United Therapeutics (UTHR) Financial Analysis & Valuation | Quarter Chart
United Therapeutics (UTHR)
UTHRPrice: $544.92
Fair Value: 🔒
🔒score
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to tre... more
United Therapeutics Corporation, a biotechnology company, engages in the development and commerciali... more
Description
Shares
| Market Cap | $23.13B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Martine A. Rothblatt |
| IPO Date | 1999-06-17 | CAGR | 0.47% |
| Employees | 1,305 | Website | www.unither.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 25.74% | Total Yield | 25.74% |
UTHR chart loading...
Fundamentals
Technicals
| Enterprise Value | $23.72B | P/E Ratio | 20.12 |
| Forward P/E | 17.15 | PEG Ratio | -1.65 |
| P/S Ratio | 3.06 | P/B Ratio | 1.67 |
| P/CF Ratio | 6.37 | P/FCF Ratio | 9.55 |
| EPS | $27.09 | EPS Growth 1Y | 7.94% |
| EPS Growth 3Y | 82.15% | EPS Growth 5Y | 198.9% |
| Revenue Growth 1Y | 5.87% | Gross Margin | 0.87% |
| Operating Margin | 0.45% | Profit Margin | 0.41% |
| ROE | 0.19% | ROA | 0.19% |
| ROCE | 0.24% | Current Ratio | 4.79 |
| Quick Ratio | 4.5 | Cash Ratio | 1.79 |
| Debt/Equity | — | Interest Coverage | 87.63 |
| Altman Z Score | 20.59 | Piotroski Score | 6 |